Lilly Seeks FDA Nod for Pill

The oral medication could provide a more convenient alternative to injectable treatments like Mounjaro and Zepbound.

Trial results showed significant weight loss and blood sugar improvement, rivaling the effectiveness of current injections.

Analysts expect the pill to be a major growth driver for Lilly as it competes with rival Novo Nordisk.

The company is also facing pressure to offer discounts as public health agencies in Canada and elsewhere consider covering the high-cost treatments.